- Allergy
- Aspergillosis
- B19 parvovirus
- Bacterial infections
- Blastomycosis
- Cancers - overview
- Candidiasis
- Cardiomyopathy
- Coccidioidomycosis
- Cryptococcus
- Cryptosporidiosis
- Cytomegalovirus (CMV) - overview
- Cytomegalovirus (CMV) - key research on treatment
- Cytomegalovirus (CMV) - key research on prophylaxis
- Cytomegalovirus (CMV) - references
- Depression
- Diabetes
- Entamoeba histolytica
- Giardia lamblia
- Gingivitis
- Guillain-Barré syndrome
- Gynaecomastia (breast enlargement)
- Hairy leukoplakia
- Hepatitis A
- Hepatitis B
- Hepatitis C - overview
- Hepatitis C - key research
- Hepatitis C - references
- Herpes simplex
- Histoplasmosis
- HIV-associated dementia - overview
- HIV-associated dementia - key research
- HIV-associated dementia - references
- HIV-associated salivary disease
- Hodgkin's disease
- Human herpes virus 6
- Human papilloma virus
- Isosporiasis
- Kaposi's sarcoma - overview
- Kaposi's sarcoma - key research
- Kaposi's sarcoma - references
- Lactic acidosis / acidaemia
- Leishmaniasis
- Lung cancer
- Lymphocytic interstitial pneumonitis
- Malaria
- Microsporidiosis
- Molluscum contagiosum
- Multicentric Castleman's disease
- Mycobacterium avium intracellulare (MAI) - overview
- Mycobacterium avium intracellulare (MAI) - key research
- Mycobacterium avium intracellulare (MAI) - references
- Mycobacterium haemophilum
- Mycobacterium kansasii
- Neuropathy
- Neutropenia
- Non-Hodgkin's lymphoma
- Osteonecrosis
- Osteoporosis
- Pancreatitis
- Pelvic inflammatory disease
- Penicilliosis
- Persistent generalised lymphadenopathy
- Pneumocystis pneumonia (PCP) - overview
- Pneumocystis pneumonia (PCP) - prevention & prophylaxis key research
- Pneumocystis pneumonia (PCP) - treatment key research
- Pneumocystis pneumonia (PCP) - references
- Progressive multifocal leukoencephalopathy (PML)
- Psoriasis
- Pulmonary arterial hypertension
- Q fever
- Renal (kidney) disease
- Salmonellosis
- Schistosomiasis and other worm and fluke infections
- Seborrhoeic dermatitis
- Syphilis
- Testicular cancer
- Testosterone deficiency
- Thrombocytopenia
- Thrombotic thrombocytopenic purpura
- Tinea
- Toxoplasmosis - overview
- Toxoplasmosis - treatment key research
- Toxoplasmosis - prophylaxis key research
- Toxoplasmosis - references
- Tuberculosis
- Ulcers
- Vacuolar myelopathy
- Varicella zoster virus
- Wasting syndrome - overview
- Wasting syndrome - key research
- Wasting syndrome - references
Mycobacterium haemophilum
Mycobacterium haemophilum is a mycobacterium, which belongs to the same family of bacteria as the causative agents of M. avium intracellulare (MAI) and tuberculosis also belong. It is unique in that it requires haemoglobin or haem for growth. Its natural habitat and the ways in which it is transmitted remain unknown.
It is rare even among immunosuppressed people such as people with AIDS. However, it can affect the skin, with the possibility of disseminating to the bones and to other organs.
Symptoms and diagnosis
Due to the very small number of reported cases and variable course of M. haemophilum infections, it is impossible to describe a clearly recognisable set of symptoms. Ulcerating skin lesions (especially on the extremities), joint effusions, and osteomyelitis have been reported. Lesions should be screened for mycobacteria with an acid-fast stain, and positive samples should be cultured in haemin-containing culture media at 30°C.
Treatment
No clinical trials of treatments for M. haemophilum have been conducted, and there is no standard treatment. Transient responses to combinations of anti-mycobacterial drugs (such as rifampicin, ciprofloxacin, ethambutol and clofazimine) have been reported.
The in vitro sensitivity of M. haemophilum isolates is widely variable, and susceptibility tests should be performed for each patient.
References
Armstrong D et al. Epidemiologic notes and reports: Mycobacterium haemophilum infections - New York City metropolitan area. Morbidity and Mortality Weekly Report 40(37): 636-643, 1991. Dever LL et al. Varied presentations and responses to treatment of infections caused by Mycobacterium haemophilum in patients with AIDS. Clinical Infectious Diseases 14: 1195-1200, 1992. Paech V et al. Remission of cutaneous Mycobacterium haemophilum infection as a result of antiretroviral therapy in a human immunodeficiency virus-infected patient. Clinical Infectious Diseases 34(7): 1017-1019, 2002. Rogers PS et al. Case reports: disseminated Mycobacterium haemophilum infection in two patients with the acquired immunodeficiency syndrome. American Journal of Science 84(3): 640-642, 1988. Soubani AO et al. Successful treatment of disseminated Mycobacterium haemophilum infection in a patient with AIDS. Clinical Infectious Diseases 18: 475-476, 1994. Straus WL et al. Clinical and epidemiologic characteristics of Mycobacterium haemophilum, an emerging pathogen in immunocompromised patients. Annals of Internal Medicine 120: 118-125, 1994.
latest aidsmap news
- Large HIV vaccine study will not go ahead
- Swiss court rules all people with HIV can be criminally liable for transmission, even if untested
- Genital shedding of HIV in women with undetectable viral load: less of it, but still happening
- Microbicides could prevent more infections in men than in women
- Knowledge of STIs poor in rural Tanzania - associated with risky sex and infection with HIV
- HIV treatment effective for infants in resource-limited settings
- Need for vigilance: two cases of abacavir allergy despite pre-treatment screening all-clear
- One third of people with HIV have experienced sexual difficulties in the past month
- Differing causes of lung infections in HIV-positive patients: implications for diagnosis and treatment
- Roche to halt HIV drug research
